Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Diabetes troglitazone

Pfizer introduced troglitazone in 1997 and marketed it as Rezulin, an oral treatment for type 2 diabetes. Warner Lambert Co., which was acquired by Pfizer in June 2000, discontinued marketing this drug in March 2000. In January 2003, the company... [Pg.10]

Troglitazone Rezulin Warner-Lambert Type 2 diabetes 1/29/1997 3/21/2000 2.16 years Liver failure US 2.1 billion worldwide... [Pg.502]

Thiazolidinediones have benefit in the prevention of type 2 diabetes. The Diabetes Prevention Trial reported a 75% reduction in diabetes incidence rate when troglitazone was administered to patients with prediabetes. Another study reported that troglitazone therapy significantly decreased the recurrence of diabetes mellitus in high-risk Hispanic women with a history of gestational diabetes. [Pg.944]

Buchanan Protection from type 2 diabetes persists in the TRIPOD cohort eight months after stopping troglitazone. Diabetes 2001 50 (Suppl 2) A81. [Pg.950]

Diabetes Prevention Program Research Group Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes 2005 54 1150. [Pg.951]

Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry RR. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 2002 51(l) 30-6. [Pg.378]

Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002 25(10) 1691-8. [Pg.379]

Insulin plus metformin (27 patients, 2000 mg/day) or troglitazone (30 patients, 600 mg/day) in patients with type 2 diabetes using at least 30 units/day was compared with insulin alone (30 patients) for 4 months (307). Body... [Pg.392]

Raskin P, Jovanovic L, Berger S, Schwartz S, Woo V, Ratner R. Repaglinide/troglitazone combination therapy improved glycemic control in type 2 diabetes. Diabetes Care 2000 23(7) 979-83. [Pg.440]

Buysschaert M, Bobbioni E, Starkie M, Frith LTroglitazone Study Group. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Diabet Med 1999 16(2) 147-53. [Pg.454]

It is possible that the combination of rosiglitazone with fenofibrate was responsible for the severe myopathy, although the possibility of a single drug cannot be excluded. Raised creatine kinase activity has been reported with troglitazone, and there has been a report of rhabdomyolysis in a patient with type 2 diabetes taking pioglitazone when fenofibrate was added. [Pg.462]

Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998 21(12) 2135-9. [Pg.469]

Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, Vanbogelen R, Leff T. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 2000 49(4) 539 17. [Pg.469]

Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999 22(6) 908-12. [Pg.469]

Frias JP, Yu JG, Kruszynska YT, Olefsky JM. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 2000 23(l) 64-9. [Pg.469]

Fujibayashi K, Nagasaka S, Itabashi N, Kawakami A, Nakamura T, Kusaka I, Ishikawa S, Saito T. Troglitazone efficacy in a subject with glucocorticoid-induced diabetes. Diabetes Care 1999 22(12) 2088-9. [Pg.469]

Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 1999 48(12) 2414-21. [Pg.469]

Scheen AJ, Lefebvre PJ. Troglitazone antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999 22(9) 1568-77. [Pg.469]

Saleh YM, Mudaliar SR, Henry RR. Metabolic and vascular effects of the thiazolidinedione troglitazone. Diabetes Rev 1999 7 55-76. [Pg.469]

Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998 47 810-4. [Pg.470]

Maher TD, Mirza SA. Ataxia and reversible dementia-like syndrome associated with troglitazone. Diabetes 1999 48(Suppl 1) A85. [Pg.471]

Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000 23(8) 1067-71. [Pg.471]

Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996 19(2) 151-6. [Pg.471]

Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosigli-tazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002 25(4) 708-11. [Pg.471]

See other pages where Diabetes troglitazone is mentioned: [Pg.340]    [Pg.359]    [Pg.159]    [Pg.837]    [Pg.503]    [Pg.514]    [Pg.119]    [Pg.5]    [Pg.65]    [Pg.354]    [Pg.345]    [Pg.225]    [Pg.368]    [Pg.369]    [Pg.392]    [Pg.437]    [Pg.459]    [Pg.459]    [Pg.460]    [Pg.461]    [Pg.467]    [Pg.469]   
See also in sourсe #XX -- [ Pg.197 ]



SEARCH



Troglitazone

© 2024 chempedia.info